Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

November 13, 2019

Study Completion Date

November 13, 2019

Conditions
Familial Alcoholism Vulnerability
Interventions
DRUG

Mavoglurant (AFQ056)

2-100mg tablets of Mavoglurant will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.

OTHER

Placebo

Two matching tablets of placebo will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.

Trial Locations (1)

06102

Hartford Hospital, Hartford

All Listed Sponsors
lead

Yale University

OTHER

NCT03341715 - Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN | Biotech Hunter | Biotech Hunter